- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
FDA requires additional phase 3 trial of Targanta antibiotic
Washington - The Food and Drug Administration (FDA) is requiring Targanta Therapeutics to conduct an additional phase 3 trial of its antibiotic oritavancin, according to fdanews.com.
Washington
- The Food and Drug Administration (FDA) is requiring Targanta Therapeutics to conduct an additional phase 3 trial of its antibiotic oritavancin, according to fdanews.com.
In order for oritavancin NDA to treat complicated skin and skin structure infections, the study must include subjects with methicillin-resistant Staphylococcus aureus, and several safety concerns must be addressed, including a high rate of participants dropping out due to lack of efficacy and serious adverse events, according to the release.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
